Merck's PD-1 star Keytruda flunks a key survival endpoint in SCLC — cue the unfavorable Tecentriq comparisons
Merck’s star checkpoint drug Keytruda missed a key endpoint in their Phase III trial as a frontline therapy for extensive-stage small cell lung cancer, failing to provide a significant improvement in overall survival.
The drug combined with chemo did hit the endpoint for significance in progression-free survival, leaving it in a weak but competitive position in this hard-to-treat form of cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,000+ biopharma pros reading Endpoints daily — and it's free.